Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.56 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11441525 | 0.85 | SMN1; SMN2 (0.71) | ALDH1A1SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL933858 | 0.84 | NPC1 (0.67) | ALDH1A1NPC1GAAMEN1KMT2A | |
| SCHEMBL23000078 | 0.84 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2NPC1GAAMEN1 | |
| SCHEMBL11146344 | 0.83 | NPC1 (0.57) | ALDH1A1SMN1; SMN2HTTNPC1MEN1 | |
| SCHEMBL5902331 | 0.83 | NPC1 (0.65) | ALDH1A1SMN1; SMN2NPC1GAAMEN1 | |
| SCHEMBL7529534 | 0.83 | NPC1 (0.65) | ALDH1A1NPC1GAAMEN1KMT2A | |
| SCHEMBL16215809 | 0.83 | NPC1 (0.65) | ALDH1A1SMN1; SMN2NPC1GAAMEN1 | |
| SCHEMBL5250976 | 0.83 | NPC1 (0.69) | ALDH1A1NPC1GAAMEN1KMT2A | |
| SCHEMBL2797868 | 0.83 | NPC1 (0.65) | ALDH1A1NPC1GAAMEN1KMT2A | |
| SCHEMBL2176443 | 0.83 | NPC1 (0.65) | ALDH1A1NPC1GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4398944-A | N-ALKOXYPHENYLMETHYL-2-CHLOROACETAMIDE | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1983-08-16 | — | — | US | claimed |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-02 | — | — | US | disclosed |
| US-20200062696-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-27 | — | — | US | disclosed |
| US-20200062696-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-27 | — | — | US | disclosed |
| US-20200054651-A1 | COMPOSITIONS AND METHODS FOR MODULATING PPP2R1A | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-20 | — | — | US | disclosed |
| US-20200054651-A1 | COMPOSITIONS AND METHODS FOR MODULATING PPP2R1A | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-20 | — | — | US | disclosed |
| CN-110785426-A | Compositions and methods for modulating PPP2R1A | 加利福尼亚大学董事会 | 2020-02-11 | — | — | CN | disclosed |
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | FRONTIER MEDICINES CORPORATION | 2019-09-26 | — | — | US | disclosed |
| WO-2018144869-A1 | COMPOSITONS AND METHODS FOR MODULATING UBA5 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018144871-A1 | COMPOSITIONS AND METHODS FOR MODULATING PPP2R1A | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-08-09 | — | — | WO | disclosed |
| US-7550458-B2 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-7326710-B2 | Aralkyl formyl-alkyl piperazine derivatives and their uses as a cerebral nerve protective agent | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2008-02-05 | — | — | US | disclosed |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-19 | — | — | US | disclosed |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-19 | — | — | US | disclosed |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-19 | — | — | US | disclosed |
| US-20050153981-A1 | Aralkyl formly-alkyl piperazine derivatives and their uses as a cerebral nerve protective agent | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2005-07-14 | — | — | US | disclosed |
| EP-1553092-A1 | ARALKYL FORMYL-ALKYL PIPERAZINE DERIVATIVES AND THEIR USES AS CEREBRAL NERVE PROTECTIVE AGENT | Shanghai Institute of Pharmaceutical Industry (CN) | 2005-07-13 | — | — | EP | disclosed |
| US-4398944-A | N-ALKOXYPHENYLMETHYL-2-CHLOROACETAMIDE | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1983-08-16 | — | — | US | disclosed |
| US-4017631-A | MICROBIOCIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1977-04-12 | — | — | US | disclosed |
| US-3991202-A | ANTIMICROBIALS | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062696-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RETICULON 4 | RTN4, RTN3, RCN1 | ALDH1A1 4014/4885SMN1; SMN2 2138/4885HTT 3215/4885 |
| US-20050153981-A1 | Aralkyl formly-alkyl piperazine derivatives and their uses as a cerebral nerve protective agent | GAP43, FABP7, AGK | ALDH1A1 1828/4885SMN1; SMN2 131/4885HTT 627/4885 |
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | ATG7, BECN1, SQSTM1 | ALDH1A1 4188/4885SMN1; SMN2 3721/4885HTT 238/4885 |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | RNF114, RNF4, RNF168 | ALDH1A1 2969/4885SMN1; SMN2 1834/4885HTT 546/4885 |
| US-20200054651-A1 | COMPOSITIONS AND METHODS FOR MODULATING PPP2R1A | PPP2R1A, PPP3CA, PPP2R2A | ALDH1A1 2930/4885SMN1; SMN2 2710/4885HTT 2415/4885 |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | VDR, ESRRB, NR5A1 | ALDH1A1 3634/4885SMN1; SMN2 4802/4885HTT 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.